Unraveling Therapeutic Prospects for Endometriosis: Modulating AKT۱ with an Established Breast Cancer Drug, Capivasertib

Endometriosis, a prevalent and debilitating gynecological disorder affecting millions ofwomen worldwide, is characterized by the presence of endometrial-like tissue outside the uterine cavity[۱]. This study explores novel therapeutic strategies for endometriosis by targeting RAC-alphaserine/threonine-protein kinase (AKT۱) with drug Capivasertib. Leveraging the Gene ExpressionOmnibus (GEO) dataset, significant alternation in gene expression patterns associated withendometriosis were identified. Network analysis using STRING and Cytoscape highlighted AKT۱ as acentral player in endometriosis-associated pathways. In silico exploration of DrugBank revealedCapivasertib, an FDA-approved inhibitor of pathway leading to AKT۱ upregulation in breast cancer[۲]. Despite no prior application in endometriosis, the potential of Capivasertib to modulate AKT۱expression introduces an innovative therapeutic hypothesis. We propose the strategic use ofCapivasertib as a transformative approach for endometriosis, building upon the established safetyprofile in breast cancer .Additionally, our in-silico investigation suggests that the upregulation of AKT۱ may serve as a potentialbiomarker for endometriosis. Differential expression levels of AKT۱ could offer diagnostic andprognostic insights, enhancing clinical assessments .This study assumes significance in addressing the unmet medical needs of individuals withendometriosis. With a dual focus on precision therapeutics and biomarker identification, the potentialimplications extend to improved patient outcomes, personalized treatment strategies, and a deeperunderstanding of molecular mechanisms driving endometriosis.

کلیدواژه ها:

Endometriosis ، AKT۱ ، Capivasertib ، Therapeutic Prospects ، Biomarker